Oxycodone News and Research

RSS
QRxPharma announces interim analysis of MoxDuo IR clinical program

QRxPharma announces interim analysis of MoxDuo IR clinical program

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Obama administration touts federal efforts to combat health care fraud

Obama administration touts federal efforts to combat health care fraud

USPTO grants Collegium second patent for tamper-resistant DETERx formulation platform

USPTO grants Collegium second patent for tamper-resistant DETERx formulation platform

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Elite Pharmaceuticals reports decrease in manufacturing revenue for fiscal first quarter

Elite Pharmaceuticals reports decrease in manufacturing revenue for fiscal first quarter

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm second-quarter total revenue increases to $6.8 million

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

Acura Pharmaceuticals reports net loss of $3.2M for second-quarter 2010

Acura Pharmaceuticals reports net loss of $3.2M for second-quarter 2010

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy

QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Investment report on Catalyst Pharmaceutical Partners

Investment report on Catalyst Pharmaceutical Partners

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

TheraQuest launches new analgesic product pipeline

TheraQuest launches new analgesic product pipeline

Elite Pharmaceuticals acquires hydromorphone hydrochloride tablets from Mikah Pharma

Elite Pharmaceuticals acquires hydromorphone hydrochloride tablets from Mikah Pharma

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.